| Literature DB >> 20142058 |
S Rybikowski1, C Maurin, J Deturmeny, V Delaporte, E Lechevallier, C Coulange.
Abstract
The spironolactone is a diuretic of potassium savings. It is also used in the treatment of the hirsutism for its antiandrogenic action. Its use and its effects on the patients affected by a prostate cancer are less known. We report the case of a 72-year-old man having a cancer of prostate which normalized its PSA after institution of a treatment by spironolactone for ascites. This patient had a biological recurrence of a prostate cancer, arisen 7 years later after a treatment by hormonal radiotherapy. Nine months after the implementation of the treatment by spironolactone, there were no clinical and biological signs of disease progress. (c) 2009. Published by Elsevier Masson SAS.Entities:
Mesh:
Substances:
Year: 2009 PMID: 20142058 DOI: 10.1016/j.purol.2009.04.002
Source DB: PubMed Journal: Prog Urol ISSN: 1166-7087 Impact factor: 0.915